SECURITIES AND EXCHANGE COMMISSION

                              Washington D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

                         Date of Report : March 3, 2000
                                          -------------

                        (Date of earliest event reported)

                             ADVANCED PHOTONIX, INC.
                             -----------------------
             (Exact Name of Registrant as specified in its Charter)



    Delaware                       1-11056                          33-00325826
-----------------                  -------                          -----------
(State or other jurisdiction     (Commission                 (IRS Employer
    incorporation)                File Number)               Identification No.)



                 1240 Avenida Acaso, Camarillo, California 93012
                 -----------------------------------------------

               (Address of Principal Executive Offices) (ZIP Code)




Registrant's telephone number,
including area code:                      (805) 987-0146
                                   ---------------------

<PAGE>

Item 5.  Other Events.

(a) On March 3, 2000 Advanced Photonix, Inc. (the "Company"),  announced that it
was  considering the  acquisition,  in a targeted stock  transaction,  of Jenner
Biotherapies   Inc.,   a  privately   held,   development-stage,   biotechnology
corporation  ("Jenner").  Mr.  Hayden Leason is the Chairman of both the Company
and Jenner and is a substantial  shareholder of Jenner.  Mr. Leason has provided
certain  information  concerning  Jenner  to the Board of  Directors  of API for
evaluation.  Such information includes details of the development status of five
compounds in the area of cancer  vaccines,  vaccine  administration,  and immune
system  responses to cancer cells.  One of the vaccine products is in a Phase II
clinical  trial and a  macrophage  activator  for  immune  system  response  has
completed  a Phase  III  clinical  trial.  The  other  products  are in  earlier
development stages.

(b) On March 7, 2000 in connection with the review of the potential  acquisition
of Jenner,  the Board of Directors  announced the  appointment of Mr. Stephen P.
Soltwedel and Mr. Richard D. Kurtz to serve on API's Board of Directors.

Mr.  Soltwedel  is  currently  Vice  President  and Chief  Financial  Officer of
Filtertek  Inc.,  ("Filtertek")  a wholly owned  subsidiary of ESCO  Electronics
(ESE),  an $80  million  injection  molder  specializing  in  filtration  to the
automotive,  medical and commercial markets. He joined Filtertek in 1972 and was
elected Vice President, Secretary and Treasurer of Filtertek Inc. and its sister
corporation, Filtertek de Puerto Rico, Inc. in 1979. In 1992, Filtertek was sold
to Schawk Inc. and subsequently  sold to ESCO  Electronics.  Mr. Soltwedel has a
BBA degree in Accounting from Madison Business College.

Mr.  Kurtz is  currently  Vice  President  Sales & Marketing  of  Filtertek  and
Strategic Business Director - Medical Business Unit. He joined Filtertek in 1988
in the Sales and Marketing  Group.  Prior to joining  Filtertek,  Mr. Kurtz held
sales  and  marketing  positions  with  companies  in the  aerospace,  consumer,
automotive  and  industrial  markets.  Mr.  Kurtz  received his MBA from Eastern
Michigan University and his BA in Economics from Michigan State University.

Mr.  Leason,  the  Chairman of the Company was the founder and former  principle
shareholder of Filtertek,  a designer and  manufacturer of specialty  filtration
equipment. Mr. Leason sold his interest in Filtertek in 1992.

A Special  Committee of the Board of Directors  composed of Messrs Soltwedel and
Kurtz has been formed to review and  evaluate  the terms of any  proposal for an
acquisition  which API may submit to Jenner.  It is anticipated that no proposed
acquisition  will be  submitted  for  shareholder  approval  unless the  Special
Committee  determines  to  recommend  such  proposal as being fair to the public
shareholders of API.

As of the date hereof, no proposal to acquire Jenner has been made by API. While
API  believes it likely that it will  formulate  and make such a proposal  based
upon its review of  information  furnished by Jenner,  there can be no assurance
that API will be able to formulate an

<PAGE>

acceptable  acquisition proposal or that any such proposal will be acceptable to
Jenner or that a transaction will be consummated.

This Current Report includes "forward looking"  statements that involve a number
of risks and  uncertainties,  including the risks of successful drug development
and  commercialization;  the risk of achieving an acquisition  agreement and the
risks  and  uncertainties  of  completing  a  successful  business  combination,
including financial, accounting and management issues.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                          ADVANCED PHOTONIX, INC.

                          By:/s/ P. J. Holmes
                             -----------------
                             Patrick J. Holmes
                             Executive Vice  President & Chief Financial Officer

Dated:  March 8, 2000
[{"type": "8-K", "sequence": "1", "description": "CURRENT REPORT", "secsgml_size_bytes": 5602}]
{"company-data": {"conformed-name": "ADVANCED PHOTONIX INC", "cik": "0000869986", "assigned-sic": "3674", "irs-number": "330325826", "state-of-incorporation": "DE", "fiscal-year-end": "0328"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-11056", "film-number": "563249"}, "business-address": {"street1": "1240 AVENIDA ACASCO", "city": "CAMARILLO", "state": "CA", "zip": "93012", "phone": "8059870146"}, "mail-address": {"street1": "1240 AVENIDA ACASO", "city": "CAMARILLO", "state": "CA", "zip": "93012"}}
SECURITIES AND EXCHANGE COMMISSION

                              Washington D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the

                         Securities Exchange Act of 1934

                         Date of Report : March 3, 2000
                                          -------------

                        (Date of earliest event reported)

                             ADVANCED PHOTONIX, INC.
                             -----------------------
             (Exact Name of Registrant as specified in its Charter)

    Delaware                       1-11056                          33-00325826
-----------------                  -------                          -----------
(State or other jurisdiction     (Commission                 (IRS Employer
    incorporation)                File Number)               Identification No.)

                 1240 Avenida Acaso, Camarillo, California 93012
                 -----------------------------------------------

               (Address of Principal Executive Offices) (ZIP Code)

Registrant's telephone number,
including area code:                      (805) 987-0146
                                   ---------------------
Item 5.  Other Events.

(a) On March 3, 2000 Advanced Photonix, Inc. (the "Company"),  announced that it
was  considering the  acquisition,  in a targeted stock  transaction,  of Jenner
Biotherapies   Inc.,   a  privately   held,   development-stage,   biotechnology
corporation  ("Jenner").  Mr.  Hayden Leason is the Chairman of both the Company
and Jenner and is a substantial  shareholder of Jenner.  Mr. Leason has provided
certain  information  concerning  Jenner  to the Board of  Directors  of API for
evaluation.  Such information includes details of the development status of five
compounds in the area of cancer  vaccines,  vaccine  administration,  and immune
system  responses to cancer cells.  One of the vaccine products is in a Phase II
clinical  trial and a  macrophage  activator  for  immune  system  response  has
completed  a Phase  III  clinical  trial.  The  other  products  are in  earlier
development stages.

(b) On March 7, 2000 in connection with the review of the potential  acquisition
of Jenner,  the Board of Directors  announced the  appointment of Mr. Stephen P.
Soltwedel and Mr. Richard D. Kurtz to serve on API's Board of Directors.

Mr.  Soltwedel  is  currently  Vice  President  and Chief  Financial  Officer of
Filtertek  Inc.,  ("Filtertek")  a wholly owned  subsidiary of ESCO  Electronics
(ESE),  an $80  million  injection  molder  specializing  in  filtration  to the
automotive,  medical and commercial markets. He joined Filtertek in 1972 and was
elected Vice President, Secretary and Treasurer of Filtertek Inc. and its sister
corporation, Filtertek de Puerto Rico, Inc. in 1979. In 1992, Filtertek was sold
to Schawk Inc. and subsequently  sold to ESCO  Electronics.  Mr. Soltwedel has a
BBA degree in Accounting from Madison Business College.

Mr.  Kurtz is  currently  Vice  President  Sales & Marketing  of  Filtertek  and
Strategic Business Director - Medical Business Unit. He joined Filtertek in 1988
in the Sales and Marketing  Group.  Prior to joining  Filtertek,  Mr. Kurtz held
sales  and  marketing  positions  with  companies  in the  aerospace,  consumer,
automotive  and  industrial  markets.  Mr.  Kurtz  received his MBA from Eastern
Michigan University and his BA in Economics from Michigan State University.

Mr.  Leason,  the  Chairman of the Company was the founder and former  principle
shareholder of Filtertek,  a designer and  manufacturer of specialty  filtration
equipment. Mr. Leason sold his interest in Filtertek in 1992.

A Special  Committee of the Board of Directors  composed of Messrs Soltwedel and
Kurtz has been formed to review and  evaluate  the terms of any  proposal for an
acquisition  which API may submit to Jenner.  It is anticipated that no proposed
acquisition  will be  submitted  for  shareholder  approval  unless the  Special
Committee  determines  to  recommend  such  proposal as being fair to the public
shareholders of API.

As of the date hereof, no proposal to acquire Jenner has been made by API. While
API  believes it likely that it will  formulate  and make such a proposal  based
upon its review of  information  furnished by Jenner,  there can be no assurance
that API will be able to formulate an
acceptable  acquisition proposal or that any such proposal will be acceptable to
Jenner or that a transaction will be consummated.

This Current Report includes "forward looking"  statements that involve a number
of risks and  uncertainties,  including the risks of successful drug development
and  commercialization;  the risk of achieving an acquisition  agreement and the
risks  and  uncertainties  of  completing  a  successful  business  combination,
including financial, accounting and management issues.

                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                          ADVANCED PHOTONIX, INC.

                          By:/s/ P. J. Holmes
                             -----------------
                             Patrick J. Holmes
                             Executive Vice  President & Chief Financial Officer

Dated:  March 8, 2000